A phase 1a dose-escalation, multicenter trial of anti-claudin 18.2 antibody drug conjugate CMG901 in patients with resistant/refractory solid tumors.

Rui‐Hua Xu(Sun Yat-sen University), Joy Yan, Dongsheng Zhang(Sun Yat-sen University), Yang Zhang(North China University of Water Resources and Electric Power), Bo Chen(Capital Medical University), Hongyun Zhao(Sun Yat-sen University), Xiaoli Wei(Anhui Medical University), Miao‐Zhen Qiu(Sun Yat-sen University)

Journal of Clinical Oncology

January 24, 2023

10.1200/jco.2023.41.4_suppl.352

Cited by 32

Related Papers

Circular RNA: metabolism, functions and interactions with proteins

|Molecular Cancer|2020|1.6k

METTL3 facilitates tumor progression via an m6A-IGF2BP2-dependent mechanism in colorectal carcinoma

|Molecular Cancer|2019|868

Erythrocyte–Platelet Hybrid Membrane Coating for Enhanced Nanoparticle Functionalization

|Advanced Materials|2017|756

Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial

|The Lancet|2023|701

The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of gastric cancer, 2021

|Cancer Communications|2021|657